File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: 7,8-dihydroxyflavone, a small molecular TrkB agonist, is useful for treating various BDNF-implicated human disorders

Title7,8-dihydroxyflavone, a small molecular TrkB agonist, is useful for treating various BDNF-implicated human disorders
Authors
KeywordsFlavonoids
Neurotrophin
BDNF
Mimetic compound
Receptor agonistic activity
Issue Date2016
PublisherBioMed Central Ltd. The Journal's web site is located at http://www.translationalneurodegeneration.com/
Citation
Translational Neurodegeneration, 2016, v. 5, p. article no. 2 How to Cite?
AbstractBrain-derived neurotrophic factor (BDNF) regulates a variety of biological processes predominantly via binding to the transmembrane receptor tyrosine kinase TrkB. It is a potential therapeutic target in numerous neurological, mental and metabolic disorders. However, the lack of efficient means to deliver BDNF into the body imposes an insurmountable hurdle to its clinical application. To address this challenge, we initiated a cell-based drug screening to search for small molecules that act as the TrkB agonist. 7,8-Dihydroxyflavone (7,8-DHF) is our first reported small molecular TrkB agonist, which has now been extensively validated in various biochemical and cellular systems. Though binding to the extracellular domain of TrkB, 7,8-DHF triggers TrkB dimerization to induce the downstream signaling. Notably, 7,8-DHF is orally bioactive that can penetrate the brain blood barrier (BBB) to exert its neurotrophic activities in the central nervous system. Numerous reports suggest 7,8-DHF processes promising therapeutic efficacy in various animal disease models that are related to deficient BDNF signaling. In this review, we summarize our current knowledge on the binding activity and specificity, structure-activity relationship, pharmacokinetic and metabolism, and the pre-clinical efficacy of 7,8-DHF against some human diseases.
Persistent Identifierhttp://hdl.handle.net/10722/281736
ISSN
2019 Impact Factor: 5.551
2015 SCImago Journal Rankings: 1.447
PubMed Central ID

 

DC FieldValueLanguage
dc.contributor.authorLiu, C-
dc.contributor.authorChan, CB-
dc.contributor.authorYe, K-
dc.date.accessioned2020-03-22T04:18:55Z-
dc.date.available2020-03-22T04:18:55Z-
dc.date.issued2016-
dc.identifier.citationTranslational Neurodegeneration, 2016, v. 5, p. article no. 2-
dc.identifier.issn2047-9158-
dc.identifier.urihttp://hdl.handle.net/10722/281736-
dc.description.abstractBrain-derived neurotrophic factor (BDNF) regulates a variety of biological processes predominantly via binding to the transmembrane receptor tyrosine kinase TrkB. It is a potential therapeutic target in numerous neurological, mental and metabolic disorders. However, the lack of efficient means to deliver BDNF into the body imposes an insurmountable hurdle to its clinical application. To address this challenge, we initiated a cell-based drug screening to search for small molecules that act as the TrkB agonist. 7,8-Dihydroxyflavone (7,8-DHF) is our first reported small molecular TrkB agonist, which has now been extensively validated in various biochemical and cellular systems. Though binding to the extracellular domain of TrkB, 7,8-DHF triggers TrkB dimerization to induce the downstream signaling. Notably, 7,8-DHF is orally bioactive that can penetrate the brain blood barrier (BBB) to exert its neurotrophic activities in the central nervous system. Numerous reports suggest 7,8-DHF processes promising therapeutic efficacy in various animal disease models that are related to deficient BDNF signaling. In this review, we summarize our current knowledge on the binding activity and specificity, structure-activity relationship, pharmacokinetic and metabolism, and the pre-clinical efficacy of 7,8-DHF against some human diseases.-
dc.languageeng-
dc.publisherBioMed Central Ltd. The Journal's web site is located at http://www.translationalneurodegeneration.com/-
dc.relation.ispartofTranslational Neurodegeneration-
dc.rightsTranslational Neurodegeneration. Copyright © BioMed Central Ltd.-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectFlavonoids-
dc.subjectNeurotrophin-
dc.subjectBDNF-
dc.subjectMimetic compound-
dc.subjectReceptor agonistic activity-
dc.title7,8-dihydroxyflavone, a small molecular TrkB agonist, is useful for treating various BDNF-implicated human disorders-
dc.typeArticle-
dc.identifier.emailChan, CB: chancb@hku.hk-
dc.identifier.authorityChan, CB=rp02140-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1186/s40035-015-0048-7-
dc.identifier.pmid26740873-
dc.identifier.pmcidPMC4702337-
dc.identifier.scopuseid_2-s2.0-84953378881-
dc.identifier.hkuros309463-
dc.identifier.volume5-
dc.identifier.spagearticle no. 2-
dc.identifier.epagearticle no. 2-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats